Value-based medicine, cost-utility analysis: The value of commonly used pharmaceuticals

Evidence-Based Ophthalmology

Volumn 10, Issue 1, 2009, Pages 61-66

  Brown, Gary C ^a   Brown, Melissa M ^a   Kertes, Peter ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CATARACT; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH INSURANCE; HEALTH STATUS; HUMAN; MEDICARE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

EID: 67650539620     PISSN: 15559203     EISSN: 15559211     Source Type: Journal    
DOI: 10.1097/IEB.0b013e3181924322     Document Type: Review

References (31)

1. Branch Retinal Vein Occlusion Study Group. Argon laser for macular edema in branch vein occlusion. Am J Ophthalmol. 1984; 98:271-282.
2. Klarman H, Francis J, Rosenthal G. Cost-effectiveness applied to the treatment of chronic renal disease. Med Care. 1968;6:48-55.
3. Weinstein MC, Stasson WB. Foundations of cost-effectiveness analysis for health and medical practices. N Eng J Med. 1977;296:716-721.
4. Gold ME, Siegel JE, Russell LB, et al. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
5. Brown MM, Brown GC, Sharma S, et al. Evidence-based medicine, utilities and quality of life. Curr Opin Ophthalmol. 1999;10:221-228.
6. Angell M. Patients' preferences in randomized clinical trials. N Eng J Med. 1984;310:1385-1387.
7. Kassirer JP. Incorporating patients' preferences into medical decisions. N Eng J Med. 1994;330: 1895-1896.
8. Steinberg EP, Tielsch JM, Schein OD, et al. The VF-14. An index of functional impairment in patients with cataract. Arch Ophthalmol. 1994; 112:630-638.
9. Ware JE Jr, Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36). Med Care. 1992;30:473-483.
10. Redelmeier DA, Detsky AS. A clinician's guide to utility measurement. In: Bergus GR, Cantor SB, eds. Primary Care. Clinics in Office Practice. Philadelphia: W.B. Saunders; 1995;22: 271-280.
11. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322-338.
12. Damodaran A. Corporate Finance. Theory and Practice. Chap 3. New York: John Wiley & Sons, Inc.; 1997:37-65.
13. Brown GC, Brown MM, Sharma S, et al. Cost-effectiveness of treatment for threshold retino-pathy of prematurity. Pediatrics. 1999;104:e47.
14. National Institute for Health and Clinical Excellence (NICE). From the Internet@www.nice.org.uk, accessed 4-5-08.
15. Heudebert GR, Centor RM, Klapow JC, et al. What is heartburn worth?Acost-utility analysis of management strategies. J Gen Intern Med. 2000;15:175-182.
16. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization. Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J. 1992;146:473-481.
17. World Health Organization. The World Health Report 2002. Reducing Risks, Promoting Healthy Life. Geneva: WHO; 2002:101-144.
18. Drummond ME, O'Brien B, Stoddart GL, et al. Methods for the Economic Evaluation of Health Care Programmes. 2nd ed. New York: Oxford University Press; 1999.
19. Brown GC, Brown MM, Sharma S. Incremental cost-effectiveness of laser therapy for subfoveal choroidal neovascularization. Ophthalmology. 2000;107:1374-1380.
20. Brown MM, Brown GC, Sharma S, et al. Health care economic analyses and value-based medicine. Surv Ophthalmol. 2003;48:204-223.
21. Brown GC, Brown MM, Sharma S. Health care in the 21st century. Evidence-based medicine, patient preference-based quality and cost-effectiveness. Qual Manage Health Care. 2000;19: 23-31.
22. Brown MM, Brown GC, Sharma S. Evidence-Based Medicine to Value-Based Medicine. Chicago: AMA Press; 2005:1-324.
23. Javitt JC, Zhou Z, Willke RJ. Association between visual loss and higher medical care costs in Medicare beneficiaries. Ophthalmology. 2007; 114:238-245.
24. Schmier JK, Halpern MT, CovertD,etal. Impact of visual impairment on use of care giving by individuals with age-related macular degeneration. Retina. 2006;26:1056-1062.
25. Busbee B, Brown MM, Brown GC, et al. Incremental cost-effectiveness of initial cataract surgery. Ophthalmology. 2002;109:606-612.
26. Busbee B, Brown MM, Brown GC, et al. A cost-utility analysis of cataract surgery in the second eye. Ophthalmology. 2003;110:2310-2317.
27. BrownGC, Brown MM, BrownH.Avalue-based medicine analysis of ranibizumab for neovascular macular degeneration - a societal investment. (Submitted for publication).
28. Brown GC, Brown MM, Brown HC, et al. A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration. Ophthalmology. 2007;114:1170-1178.
29. Cheng AK, Rubin HR, Powe NR, et al. Costutility analysis of the cochlear implant in children. JAMA. 2000;284:850-856.
30. Brown GC, Brown MM, Sharma S, et al. A cost-utility analysisof interventions for proliferative vitreoretinopathy. Am J Ophthalmol. 2002;133: 365-372.
31. Douzdjian V, Escobar F, Kupin WL, et al. Cost-utility analysis of living-donor kidney transplantation followed by pancreas transplantation versus simultaneous pancreas-kidney transplantation. Clin Transplant. 1999;13: 51-58.